Literature DB >> 25882801

10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient.

Emmanuelle Kempf1, David Planchard2, Thierry Le Chevalier2, Jean-Charles Soria3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25882801     DOI： 10.1183/09031936.00017315

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  7 in total

1.  Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis.

Authors:  Chen-Yang Huang; Bo-Huan Chen; Wen-Chi Chou; Cheng-Ta Yang; John Wen-Cheng Chang
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

2.  Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report.

Authors:  Taiji Kuwata; Kazue Yoneda; Kenichi Kobayashi; Rintarou Oyama; Hiroki Matumiya; Shuichi Shinohara; Masaru Takenaka; Soichi Oka; Yasuhiro Chikaishi; Naoko Imanishi; Koji Kuroda; Fumihiro Tanaka
Journal:  Case Rep Oncol       Date:  2016-10-04

3.  Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.

Authors:  Xiao-Feng Li; Wei-Zhang Shen; Xin Jin; Ping Ren; Jie Zhang
Journal:  Sci Rep       Date:  2020-07-08       Impact factor: 4.379

4.  Secondary Brain Neoplasm after Stereotactic Radiosurgery in Patients with Metastatic Non-small Cell Lung Cancer.

Authors:  Shigenari Nukaga; Katsuhiko Naoki; Hiroyuki Yasuda; Ichiro Kawada; Kentaro Ohara; Kenzo Soejima; Tomoko Betsuyaku
Journal:  Intern Med       Date:  2018-03-09       Impact factor: 1.271

5.  Maintained Complete Response and Long-Term Survival in Epidermal Growth Factor Receptor Mutated Metastatic Non-Small Cell Lung Cancer with Erlotinib.

Authors:  Samer Alkassis; Bayan Alshare; Shabbir Ahmed
Journal:  Cureus       Date:  2021-01-03

6.  A case report of metastatic lung adenocarcinoma with long-term survival for over 11 years.

Authors:  Tatsu Matsuzaki; Eri Iwami; Kotaro Sasahara; Aoi Kuroda; Takahiro Nakajima; Takeshi Terashima
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

7.  Extensive-disease small cell lung cancer, multiple relapses, five lines of therapy and more than 10-year survival.

Authors:  Pawan Kumar Singh; Deepa Kumari Shrestha; Navneet Singh; Nalini Gupta
Journal:  BMJ Case Rep       Date:  2020-02-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.